Cannabinoids for the treatment of post-traumatic stress disorder: a review of the clinical effectiveness and guidelines
Mujoomdar M, Spry C, Banks R
Record ID 32011001226
English
Authors' recommendations:
Overall, the evidence regarding the clinical effectiveness of cannabinoids for the treatment of PTSD is limited. The one included study concluded that the synthetic cannabinoid nabilone was effective in treating patients with PTSD who were experiencing treatment-resistant nightmares. Approximately 70% of patients enrolled in the trial experienced either a reduction in frequency or intensity, or complete cessation of nightmares while taking nabilone. None of the three evidence-based guidelines discussed the use of cannabinoids in the management of PTSD. All three of the guidelines recommended the use of CBT or SSRIs for the treatment of patients with PTSD.Overall, the evidence regarding the clinical effectiveness of cannabinoids for the treatment of PTSD is limited. The paucity of information may wish to be considered when making decisions regarding coverage of cannabinoids or the clinical use of cannabinoids for PTSD.
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/media/pdf/L0144_Cannabinoids_for_PTSD_final.pdf
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Stress Disorders, Post-Traumatic
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.